Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xiamen Amoytop Biotech CoSHSE:688278 +2.94%75 Net Margin % is 20.62% as of Mar. 2026, which is 34% above its 10-year median of 15.34. GuruFocus rates SHSE:688278 with a GF Score™ of 75/100 and a GF Value™ of ¥106.91 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Xiamen Amoytop Biotech Co ranks better than 89.48% on this metric.
The historical rank and industry rank for Xiamen Amoytop Biotech Co's Net Margin % or its related term are showing as below:
SHSE:688278'
s Net Margin % Range Over the Past 10 Years
Min: 1.6 Med: 15.34 Max: 29.38
Current: 26.53
SHSE:688278's Net Margin % is ranked better than 89.48% of 941
companies
in the Biotechnology industry
Industry Median: -89.56
vs SHSE:688278: 26.53
Xiamen Amoytop Biotech Co (SHSE:688278) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Xiamen Amoytop Biotech Co Net Margin % Related Terms
Xiamen Amoytop Biotech Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688278 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Xiamen Amoytop Biotech Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xiamen Amoytop Biotech Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xiamen Amoytop Biotech Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Xiamen Amoytop Biotech Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xiamen Amoytop Biotech Co (SHSE:688278) has a Net Margin % of 20.62% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Xiamen Amoytop Biotech Co and its competitors. This is 34% above median its historical median of 15.34. Over the past decade, Xiamen Amoytop Biotech Co's Net Margin % has ranged from 1.60 to 29.38. According to the industry distribution chart, Xiamen Amoytop Biotech Co ranks #99 out of 941 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Xiamen Amoytop Biotech Co's Net Margin % too high?
Xiamen Amoytop Biotech Co's current Net Margin % of 20.62% is 34% above median its 10-year median of 15.34. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 29.38. Based on the distribution chart, Xiamen Amoytop Biotech Co ranks #99 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xiamen Amoytop Biotech Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xiamen Amoytop Biotech Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xiamen Amoytop Biotech Co ranks #99 out of 941 companies for Net Margin %. This places Xiamen Amoytop Biotech Co in the top 11% of its industry — outperforming the majority of peers. Historically, Xiamen Amoytop Biotech Co's own Net Margin % has ranged from 1.60 to 29.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Xiamen Amoytop Biotech Co and its competitors. Xiamen Amoytop Biotech Co's current Net Margin % is 20.62%, which is 34% above median its own 10-year median of 15.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xiamen Amoytop Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co (SHSE:688278) is currently considered Possible Value Trap. The stock's GF Value™ is ¥106.91, compared to a current price of ¥60.63 — trading 43.3% below its estimated fair value. The current Net Margin % is 20.62%, which is 34% above median its 10-year median of 15.34. Xiamen Amoytop Biotech Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Xiamen Amoytop Biotech Co (SHSE:688278), the current Net Margin % is 20.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xiamen Amoytop Biotech Co (SHSE:688278) Overvalued in 2026?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co stock appears to be undervalued.
The current stock price of ¥60.63 is trading 43.3% below its estimated GF Value™ of ¥106.91.
GuruFocus considers Xiamen Amoytop Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688278:
Net Margin %: 20.62% (34% above median its 10-year median of 15.34)
GF Value™: ¥106.91 vs. price of ¥60.63 (43.3% below fair value)
No single metric tells the full story. See the SHSE:688278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
75GF Score
Get the complete analysis for SHSE:688278
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688278 has been successfully added to your 
